- Home
- PRFX vs JAGX Comparison
PRFX vs JAGX Comparison
Compare PRFX & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- JAGX
- Stock Information
- Founded
- PRFX 2007
- JAGX 2013
- Country
- PRFX Israel
- JAGX United States
- Employees
- PRFX N/A
- JAGX N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- JAGX Health Care
- Exchange
- PRFX Nasdaq
- JAGX Nasdaq
- Market Cap
- PRFX 3.3M
- JAGX 3.9M
- IPO Year
- PRFX 2020
- JAGX N/A
- Fundamental
- Price
- PRFX $1.63
- JAGX $1.65
- Analyst Decision
- PRFX Hold
- JAGX Strong Buy
- Analyst Count
- PRFX 1
- JAGX 1
- Target Price
- PRFX N/A
- JAGX $60.00
- AVG Volume (30 Days)
- PRFX 8.7M
- JAGX 142.0K
- Earning Date
- PRFX 09-16-2025
- JAGX 08-14-2025
- Dividend Yield
- PRFX N/A
- JAGX N/A
- EPS Growth
- PRFX N/A
- JAGX N/A
- EPS
- PRFX N/A
- JAGX N/A
- Revenue
- PRFX N/A
- JAGX $11,810,000.00
- Revenue This Year
- PRFX N/A
- JAGX $22.41
- Revenue Next Year
- PRFX N/A
- JAGX $30.00
- P/E Ratio
- PRFX N/A
- JAGX N/A
- Revenue Growth
- PRFX N/A
- JAGX 15.96
- 52 Week Low
- PRFX $1.25
- JAGX $1.57
- 52 Week High
- PRFX $16.63
- JAGX $35.25
- Technical
- Relative Strength Index (RSI)
- PRFX 53.13
- JAGX 32.57
- Support Level
- PRFX $1.34
- JAGX $1.57
- Resistance Level
- PRFX $1.92
- JAGX $1.70
- Average True Range (ATR)
- PRFX 0.27
- JAGX 0.11
- MACD
- PRFX -0.02
- JAGX 0.00
- Stochastic Oscillator
- PRFX 13.05
- JAGX 14.55
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.